Founded by Dr. Mark Pruzanski in 2002, Intercept had previously raised about $45m from private investors, including Italy-based Genextra, US-based venture capital firm Visium and Jafco Life Science Investment, which raised about a quarter of its latest near Y240bn ($3bn) fund from corporations.
Intercept Pharmaceuticals, a US-based liver drugs maker based on work at Italy’s University of Perugia, has raised $30m in its series C round. Venture capital firm OrbiMed Advisors led the C round, with Intercept’s majority investor, Genextra, also participating. Genextra was created in 2004 by a group of Italian entrepreneurs and financial institutions in partnership…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
